<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:57:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8678301" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8678301</identifier>
        <datestamp>2022-06-15</datestamp>
        <setSpec>aacrsd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
              <journal-title-group>
                <journal-title>Clinical Cancer Research</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1078-0432</issn>
              <issn pub-type="epub">1557-3265</issn>
              <publisher>
                <publisher-name>American Association for Cancer Research</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8678301</article-id>
              <article-id pub-id-type="pmcid">PMC8678301</article-id>
              <article-id pub-id-type="pmc-uid">8678301</article-id>
              <article-id pub-id-type="pmid">34551907</article-id>
              <article-id pub-id-type="pmid">34551907</article-id>
              <article-id pub-id-type="publisher-id">CCR-21-2139</article-id>
              <article-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2139</article-id>
              <article-version id="ver1" article-version-type="VoR">Version of Record</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Perspectives</subject>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Drug Resistance</subject>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Epigenetics</subject>
                  <subj-group subj-group-type="category">
                    <subject>DNA methylation</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Hematological Cancers</subject>
                  <subj-group subj-group-type="category">
                    <subject>Leukemias</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions</article-title>
                <alt-title alt-title-type="short">Hypomethylating Agent Combination Trial Failures</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7888-385X</contrib-id>
                  <name>
                    <surname>Zavras</surname>
                    <given-names>Phaedon D.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shastri</surname>
                    <given-names>Aditi</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4347-173X</contrib-id>
                  <name>
                    <surname>Goldfinger</surname>
                    <given-names>Mendel</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Verma</surname>
                    <given-names>Amit K.</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff"/>
                  <xref rid="cor1" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9757-1031</contrib-id>
                  <name>
                    <surname>Saunthararajah</surname>
                    <given-names>Yogen</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff"/>
                  <xref rid="cor1" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York.</aff>
              <aff id="aff2"><label>2</label>Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.</aff>
              <aff id="aff3"><label>3</label>Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.</aff>
              <author-notes>
                <corresp id="cor1"><label>*</label><bold>Corresponding Authors:</bold> Yogen Saunthararajah, Taussig Cancer Institute, Cleveland Clinic, C302B, 1300 Morris Park Avenue, Bronx, NY 10461. E-mail: <email>saunthy@ccf.org</email>; and Amit K. Verma, <email>amit.verma@einsteinmed.org</email></corresp>
                <fn fn-type="other">
                  <p>Clin Cancer Res 2021;27:6653–61</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub" iso-8601-date="2021-12-15">
                <day>15</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>15</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <volume>27</volume>
              <issue>24</issue>
              <fpage>6653</fpage>
              <lpage>6661</lpage>
              <history>
                <date date-type="received" iso-8601-date="2021-07-06">
                  <day>06</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd" iso-8601-date="2021-08-19">
                  <day>19</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted" iso-8601-date="2021-09-17">
                  <day>17</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>©2021 The Authors; Published by the American Association for Cancer Research</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>American Association for Cancer Research</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="6653.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec>
                  <title>Purpose:</title>
                  <p>Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies for myelodysplastic syndromes and acute myelogenous leukemias. Several attempts to improve outcomes by combining HMAs with investigational agents, excepting with the BCL2-inhibitor venetoclax, have failed in randomized clinical trial (RCT) evaluations. We extract lessons from decades of clinical trials to thereby inform future work.</p>
                </sec>
                <sec>
                  <title>Experimental Design:</title>
                  <p>Serial single-agent clinical trials were analyzed for mechanism and pathway properties of HMAs underpinning their success, and for rules for dose and schedule selection. RCTs were studied for principles, dos and don'ts for productive combination therapy.</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>Single-agent HMA trial results encourage dose and schedule selection to increase S-phase–dependent DNMT1 targeting, and discourage doses that cause indiscriminate antimetabolite effects/cytotoxicity, because these attrit myelopoiesis reserves needed for clinical response. Treatment-related myelosuppression should prompt dose/frequency reductions of less active investigational agents rather than more active HMA. Administering cytostatic agents concurrently with HMA can antagonize S-phase–dependent DNMT1 targeting. Supportive care that enables on-time administration of S-phase (exposure-time)–dependent HMA could be useful. Agents that manipulate pyrimidine metabolism to increase HMA pro-drug processing into DNMT1-depleting nucleotide, and/or inhibit other epigenetic enzymes implicated in oncogenic silencing of lineage differentiation, could be productive, but doses and schedules should adhere to therapeutic index/molecular–targeted principles already learned.</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>More than 40 years of clinical trial history indicates mechanism, pathway, and therapeutic index properties of HMAs that underpin their almost exclusive success and teaches lessons for selection and design of combinations aiming to build on this treatment foundation.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart, Lung and Blood Institute</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>PO1 HL146372</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30 CA043703</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>RO1 CA204373</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>Lung and Blood Institute</institution>
                      <institution-id institution-id-type="DOI">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01HL139487</award-id>
                  <award-id>R01HL150832</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>Albert Einstein Cancer Center Support</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30CA013330</award-id>
                </award-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution>V Foundation for Cancer Research</institution>
                      <institution-id institution-id-type="DOI">10.13039/100001368</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>Verma</surname>
                      <given-names>A.K.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <!--<fig-count count="3"/>-->
                <!--<table-count count="2"/>-->
                <!--<equation-count count="0"/>-->
                <!--<ref-count count="51"/>-->
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <boxed-text position="margin" id="b1">
              <caption>
                <title>Translational Relevance</title>
              </caption>
              <p>Hypomethylating agents (HMA), the small-molecule drugs azacitidine and decitabine that target DNA methyltransferase 1, are mainstays for treating myeloid malignancies, for example, myelodysplastic syndromes and acute myelogenous leukemias. Several attempts to improve outcomes by combining HMAs with investigational agents, excepting with the BCL2 inhibitor venetoclax, have failed in expensive, randomized clinical trial evaluations. We extract lessons from successes and failures over &gt;40 years of clinical trials and mechanism studies to inform and guide future combination therapy trials.</p>
            </boxed-text>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>The small-molecule drugs azacitidine (5-azacytidine) and decitabine (5-aza-2′-deoxycytidine) are DNA hypomethylating agents (HMA). That is, both agents inhibit and deplete the key epigenetic regulator DNA methyltransferase enzyme 1 (DNMT1). DNMT1 is the “maintenance methyltransferase” that copies methylation marks of the parental DNA strand onto the newly synthesized strand during cell-cycle S-phase, and is also a corepressor (a protein mediating gene repression) recruited to gene loci by lineage master transcription factors. The HMAs are the most effective single agents for treating myelodysplastic syndromes (MDS) and acute myelogenous leukemias (AML), with response rates of approximately 35%–60%. Numerous attempts to further improve outcomes by combining HMAs with investigational drugs, however, have failed in randomized controlled clinical trials (RCT), except for combinations with the BCL2 inhibitor venetoclax. We extract from this hard-fought history: (i) properties of HMAs that can explain their success versus numerous other single agents, so that future trials can seek to preserve or enhance these properties; (ii) principles for HMA dose and schedule selection, taught by serial HMA single-agent studies; (iii) classes of agents to consider for combination therapy, suggested by successful RCTs; (iv) lessons learned from unsuccessful RCTs, to avoid repeating previous miscalculations. In this way, we can hopefully increase likelihoods of future success.</p>
              <sec id="sec1-1">
                <title>Mechanism and pathway properties of HMAs to preserve or enhance</title>
                <p>Azacitidine and decitabine are the only drugs approved, and routinely used as single agents, to treat all subtypes of MDS, succeeding where cytarabine, hydroxyurea, topotecan, fosteabine, gemcitabine, irinotecan, daunorubicin, etoposide, and many other drugs failed over several decades of clinical trials. These other drugs are cytotoxic, that is, their intended mechanism is DNA damage that upregulates the transcription factor p53 (<italic toggle="yes">TP53</italic>) and its downstream apoptosis transcriptional programs (reviewed in ref. <xref rid="bib1" ref-type="bibr">1</xref>). Attenuation of p53 or its major cofactors by mutations/deletion of <italic toggle="yes">TP53</italic>, amplifications of MDM2/4, and/or by other means (<xref rid="bib1" ref-type="bibr">1–3</xref>), is, however, characteristic of malignant transformation of most tissue lineages, including myeloid. Thus, there can be upfront resistance to cytotoxic treatments (primary refractory), or ready selection by first-line cytotoxic treatments for the most apoptosis-attenuated malignant sub-clones that then resist next-line cytotoxic treatments also (relapsed-refractory; ref. <xref rid="bib1" ref-type="bibr">1</xref>). <italic toggle="yes">TP53</italic> mutations are hence negative-prediction biomarkers for cytarabine-based cytotoxic therapy, the historical standard for treating AML (<xref rid="bib4" ref-type="bibr">4</xref>). Meanwhile, normal dividing hematopoietic stem and progenitor cells (HSPC) do undergo apoptosis, because these have intact p53, thereby exacerbating or causing low blood counts (<xref rid="bib3" ref-type="bibr">3, 5</xref>). This is problematic because morbidity and death in MDS/AML is usually from low normal blood counts to begin with, and clinical response/benefit requires not just cytoreduction of malignant clones, but blood count recoveries mounted by functional HSPC. Amplifying this problem, reserves of functional HSPC diminish markedly with age (reviewed in ref. <xref rid="bib6" ref-type="bibr">6</xref>) and the majority of patients with MDS/AML are &gt;60 years of age.</p>
                <p>By contrast, HMA efficacy does not depend on p53-dependent apoptosis: DNMT1 targeting prompts MDS/AML cells to terminal differentiation, exits from cell cycle that do not require p53 (refs. <xref rid="bib1" ref-type="bibr">1–3</xref>;<xref rid="fig1" ref-type="fig">Figs. 1</xref> and <xref rid="fig2" ref-type="fig">2</xref>). In normal HSPCs, DNMT1 targeting is not inherently cytotoxic but preserves lineage maturation in the case of committed progenitors, or self-renewal in the case of stem cells, thus sparing these vital cells (refs. <xref rid="bib5" ref-type="bibr">5, 7–10</xref>; <xref rid="fig1" ref-type="fig">Fig. 1</xref>). That is, DNMT1 targeting can terminate malignant but not normal hematopoietic stem cell self-replications (good therapeutic index). Accordingly, <italic toggle="yes">TP53</italic> mutation and/or deletion is not a negative predictive biomarker for HMA clinical activity. In a randomized comparison of azacitidine 75 mg/m<sup>2</sup>/d for 7 days every 28 days versus conventional care regimens, including standard cytotoxic induction therapy with cytarabine and daunorubicin, in patients with newly diagnosed AML, subset analysis of patients with chromosome 17p (<italic toggle="yes">TP53</italic>) abnormalities (<italic toggle="yes">n</italic> = 46) found median overall survival (OS) of 5 versus 2.8 months (log-rank <italic toggle="yes">P</italic> value = 0.07; ref. <xref rid="bib11" ref-type="bibr">11</xref>). Although this analysis was limited by the small patient number, single-arm studies from more than one other institution have also documented meaningful responses to HMA in patients with <italic toggle="yes">TP53</italic>-mutated disease, and more generally, in the very elderly with high-risk disease and diminished myelopoietic reserves (<xref rid="bib2" ref-type="bibr">2, 3, 12, 13</xref>). Having said this, <italic toggle="yes">TP53</italic> abnormalities are still very much an adverse prognostic biomarker in HMA-treated patients; although clinically meaningful hematologic responses occur, these responses are short-lived (<xref rid="bib11" ref-type="bibr">11</xref>). Even though HMAs have been shown scientifically to not require p53 to antagonize MYC and terminate malignant replication, p53 inactivation upregulates the endogenous <italic toggle="yes">de novo</italic> pyrimidine synthesis pathway that directly antagonizes the DNMT1-depleting nucleotide (<xref rid="fig2" ref-type="fig">Fig. 2E</xref> and <xref rid="fig2" ref-type="fig">F</xref>; ref. <xref rid="bib14" ref-type="bibr">14</xref>; reviewed in ref. <xref rid="bib15" ref-type="bibr">15</xref>). In sum, there remains a need to enhance therapy. Mechanism and clinical trial data thus far suggest that such efforts should seek to preserve or enhance a normal HSPC-sparing, p53-independent mechanism-of-action of HMAs, properties that distinguish HMAs from numerous less or non-beneficial evaluated drugs (<xref rid="fig1" ref-type="fig">Figs. 1</xref> and <xref rid="fig2" ref-type="fig">2</xref>; <xref rid="tbl1" ref-type="table">Table 1</xref>).</p>
                <fig position="float" id="fig1">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Decitabine (Dec) and azacitidine (5Aza) are processed by pyrimidine metabolism into various metabolites, causing various molecular pharmacodynamic and pathway effects. <bold>A,</bold> Dec and 5Aza have the identical pyrimidine ring modification, but Dec has a deoxyribose and 5Aza a ribose sugar moiety—this channels their metabolism differently. <bold>B,</bold> One metabolic product is Aza-dCTP, which after incorporation into DNA during cell-cycle S-phase depletes DNMT1. Relative to decitabine, the fraction of an administered dose of 5-azacytidine that is processed into Aza-dCTP is approximately 1/10th. That is, for DNMT1-depleting goals, decitabine:5-azacytidine dose-equivalence is approximately 1:10, for example, decitabine 7.5 mg/m<sup>2</sup> ≈ 5-azacytidine 75 mg/m<sup>2</sup>. <bold>C,</bold> Other metabolites impact DNA and RNA metabolism in different ways—most of 5Aza is incorporated into RNA. <bold>D,</bold> The DNMT1-depleting action uniquely can terminate malignant self-replication and proliferation, via a p53-independent pathway, while sparing the self-replication of normal hematopoietic stem cells (good therapeutic index). This DNMT1-depleting action/pathway is saturated at relatively low Dec or 5Aza concentrations, and is S-phase dependent. In addition to inducing terminal differentiation of malignant cells, DNMT1 depletion in cancer cell lines has been shown to induce expression of self, double-stranded RNA from hypomethylated repetitive elements, that in turn can trigger type 1 interferon production and RNase L–mediated cell death.</p>
                  </caption>
                  <alt-text>Figure 1. Decitabine (Dec) and azacitidine (5Aza) are processed by pyrimidine metabolism into various metabolites, causing various molecular pharmacodynamic and pathway effects. A, Dec and 5Aza have the identical pyrimidine ring modification, but Dec has a deoxyribose and 5Aza a ribose sugar moiety—this channels their metabolism differently. B, One metabolic product is Aza-dCTP, which after incorporation into DNA during cell-cycle S-phase depletes DNMT1. Relative to decitabine, the fraction of an administered dose of 5-azacytidine that is processed into Aza-dCTP is approximately 1/10th. That is, for DNMT1-depleting goals, decitabine:5-azacytidine dose-equivalence is approximately 1:10, for example, decitabine 7.5 mg/m2 ≈ 5-azacytidine 75 mg/m2. C, Other metabolites impact DNA and RNA metabolism in different ways—most of 5Aza is incorporated into RNA. D, The DNMT1-depleting action uniquely can terminate malignant self-replication and proliferation, via a p53-independent pathway, while sparing the self-replication of normal hematopoietic stem cells (good therapeutic index). This DNMT1-depleting action/pathway is saturated at relatively low Dec or 5Aza concentrations, and is S-phase dependent. In addition to inducing terminal differentiation of malignant cells, DNMT1 depletion in cancer cell lines has been shown to induce expression of self, double-stranded RNA from hypomethylated repetitive elements, that in turn can trigger type 1 interferon production and RNase L–mediated cell death.</alt-text>
                  <graphic xlink:href="6653fig1" position="float"/>
                </fig>
                <fig position="float" id="fig2">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Known mechanisms of resistance to cytarabine (Ara-C), decitabine (Aza-dC), and 5-azacytidine (Aza-C). <bold>A,</bold> In addition to inactivating mutations in the p53 system, for example, <italic toggle="yes">TP53</italic> mutation, resistance to Ara-C is mediated by changes in pyrimidine metabolism, for example, upregulation of the catabolic enzyme cytidine deaminase (CDA) or of <italic toggle="yes">de novo</italic> pyrimidine synthesis that generates natural dCTP that competes with Ara-CTP for incorporation into DNA. dCTP also allosterically regulates DCK activity (although Ara-C appears to be a ribonucleotide by chemical formula, by structure it is processed as a deoxyribonucleotide). <bold>B,</bold> Pyrimidine metabolism shifts mediate resistance to Aza-dC. <bold>C,</bold> Pyrimidine metabolism shifts mediate resistance to Aza-C. <bold>D,</bold> These pyrimidine metabolism shifts can occur automatically (auto-resistance). TYMS depletion by Dec (or Ara-C), and RRM1 depletion by 5Aza, increase and decrease dCTP levels, respectively, prompting automatic compensatory metabolic shifts. Aza-dC and Aza-C drive DCK and UCK2 in opposite directions, but both agents upregulate the catabolic enzyme CDA and the initial enzyme in <italic toggle="yes">de novo</italic> pyrimidine synthesis—carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD). <bold>E,</bold> Even though Aza-dC and Aza-C do not require p53 to antagonize MYC, p53 inactivation upregulates CAD to potentially antagonize Aza-dCTP with endogenous dCTP. Mean±SD. TCGA RNA-Seq, <italic toggle="yes">n</italic> = 167; <italic toggle="yes">P</italic> value two-sided <italic toggle="yes">t</italic> test. <bold>F,</bold> This observation is recapitulated in hematopoietic malignancy cell lines. CCLE RNA-Seq, <italic toggle="yes">n</italic> = 175.</p>
                  </caption>
                  <alt-text>Figure 2. Known mechanisms of resistance to cytarabine (Ara-C), decitabine (Aza-dC), and 5-azacytidine (Aza-C). A, In addition to inactivating mutations in the p53 system, for example, TP53 mutation, resistance to Ara-C is mediated by changes in pyrimidine metabolism, for example, upregulation of the catabolic enzyme cytidine deaminase (CDA) or of de novo pyrimidine synthesis that generates natural dCTP that competes with Ara-CTP for incorporation into DNA. dCTP also allosterically regulates DCK activity (although Ara-C appears to be a ribonucleotide by chemical formula, by structure it is processed as a deoxyribonucleotide). B, Pyrimidine metabolism shifts mediate resistance to Aza-dC. C, Pyrimidine metabolism shifts mediate resistance to Aza-C. D, These pyrimidine metabolism shifts can occur automatically (auto-resistance). TYMS depletion by Dec (or Ara-C), and RRM1 depletion by 5Aza, increase and decrease dCTP levels, respectively, prompting automatic compensatory metabolic shifts. Aza-dC and Aza-C drive DCK and UCK2 in opposite directions, but both agents upregulate the catabolic enzyme CDA and the initial enzyme in de novo pyrimidine synthesis—carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD). E, Even though Aza-dC and Aza-C do not require p53 to antagonize MYC, p53 inactivation upregulates CAD to potentially antagonize Aza-dCTP with endogenous dCTP. Mean±SD. TCGA RNA-Seq, n = 167; P value two-sided t test. F, This observation is recapitulated in hematopoietic malignancy cell lines. CCLE RNA-Seq, n = 175.</alt-text>
                  <graphic xlink:href="6653fig2" position="float"/>
                </fig>
                <table-wrap position="float" id="tbl1">
                  <label>Table 1.</label>
                  <caption>
                    <p>Molecular targets and downstream pathways of investigational agents evaluated in combination with HMAs.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">#</th>
                        <th align="left" rowspan="1" colspan="1">Drug</th>
                        <th align="left" rowspan="1" colspan="1">Molecular-target/molecular-pharmacodynamic effect</th>
                        <th align="left" rowspan="1" colspan="1">Pathway activated in malignant myeloid cells</th>
                        <th align="left" rowspan="1" colspan="1">Pathway activated in normal hematopoietic cells</th>
                        <th align="left" rowspan="1" colspan="1">References</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">Decitabine (HMA)</td>
                        <td align="left" rowspan="1" colspan="1">DNMT1 depletion (at &lt;0.5–1 μmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">S-phase dependent; terminal differentiation (p53-independent cytoreduction)</td>
                        <td align="left" rowspan="1" colspan="1">Self-replication in normal HSC, terminal differentiation in normal committed progenitors</td>
                        <td align="left" rowspan="1" colspan="1">(3, 5, 10)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">TYMS depletion; DNA-protein adducts exceeding cellular capacity for repair (at &gt;0.5–1 μmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">Cell-cycle dependent; DNA damage and apoptosis (p53-dependent cytoreduction)</td>
                        <td align="left" rowspan="1" colspan="1">DNA damage and apoptosis (cytotoxicity)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">Azacitidine (HMA)</td>
                        <td align="left" rowspan="1" colspan="1">DNMT1 depletion (at &lt;1–5 μmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">S-phase dependent; terminal differentiation (p53 independent)</td>
                        <td align="left" rowspan="1" colspan="1">Self-replication in normal hematopoietic stem cells, terminal differentiation in normal committed progenitors</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">RRM1 depletion; DNA-protein adducts exceeding cellular capacity for repair (at &gt;0.5–1 μmol/L)</td>
                        <td align="left" rowspan="1" colspan="1">Cell-cycle dependent; DNA damage and apoptosis (p53 dependent)</td>
                        <td align="left" rowspan="1" colspan="1">DNA damage and apoptosis (cytotoxicity)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">Histone deacetylase inhibitors (entinostat, pracinostat, vorinostat, etc.)</td>
                        <td align="left" rowspan="1" colspan="1">Histone deacetylase enzyme (HDAC1, HDAC2, HDAC3, HDAC6, HDAC7) inhibition</td>
                        <td align="left" rowspan="1" colspan="1">Terminal differentiation; DNA damage; other cellular damage (because of diverse cell physiology roles of HDACs not confined to epigenetic regulation; p53-independent and p53-dependent cytoreduction)</td>
                        <td align="left" rowspan="1" colspan="1">Self-replication in normal HSC, terminal differentiation in normal committed progenitors; also DNA and other cellular damage causing apoptosis (cytotoxicity) and cytostasis (<italic toggle="yes">mixed effects that cannot be separated using different concentrations or dosages</italic>)</td>
                        <td align="left" rowspan="1" colspan="1">(47–50)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">Lenalidomide</td>
                        <td align="left" rowspan="1" colspan="1">Cerebelon ubiquitin ligase (CRBN) gain-of-function</td>
                        <td align="left" rowspan="1" colspan="1">Altered substrate specificity of cerebelon, increases proteosomal degradation of substrates that vary with cellular context, triggering apoptosis (p53 dependent); may alter progenitor lineage-commitment decisions</td>
                        <td align="left" rowspan="1" colspan="1">Apoptosis (cytotoxicity) and cytostasis (but not profound)</td>
                        <td align="left" rowspan="1" colspan="1">(51)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">Gilteritinib</td>
                        <td align="left" rowspan="1" colspan="1">FMS-related receptor tyrosine kinase 3 (FLT3) inhibition</td>
                        <td align="left" rowspan="1" colspan="1">Augments activity of the myeloid master transcription factor CEBPA to promote terminal differentiation; may inhibit <italic toggle="yes">de novo</italic> pyrimidine synthesis, and in this way augment activity of pyrimidine nucleoside analogs</td>
                        <td align="left" rowspan="1" colspan="1">Decrease normal hematopoietic precursor replication</td>
                        <td align="left" rowspan="1" colspan="1">(41)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6</td>
                        <td align="left" rowspan="1" colspan="1">Eprenetapopt</td>
                        <td align="left" rowspan="1" colspan="1">Stabilizer of p53 protein</td>
                        <td align="left" rowspan="1" colspan="1">Apoptosis in stressed cells</td>
                        <td align="left" rowspan="1" colspan="1">
                          <italic toggle="yes">Not described</italic>
                        </td>
                        <td align="left" rowspan="1" colspan="1">(42)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="left" rowspan="1" colspan="1">Eltrombopag</td>
                        <td align="left" rowspan="1" colspan="1">Thrombopoietin receptor agonist; TET dioxygenase enzyme inhibition</td>
                        <td align="left" rowspan="1" colspan="1">Inhibition of TET enzymes might be synthetic lethal in TET-deficient malignant myeloid cells; cytostatic effects by unknown mechanism</td>
                        <td align="left" rowspan="1" colspan="1">Increase normal HSC self-replication; increase multipotent progenitor commitment into megakaryocyte lineage; increase megakaryocyte differentiation</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="left" rowspan="1" colspan="1">Venetoclax</td>
                        <td align="left" rowspan="1" colspan="1">BCL2 antagonist</td>
                        <td colspan="2" align="left" rowspan="1">Mitochondrial depolarization that depowers several metabolic functions of mitochondria, and that at its most extreme activates apoptosis (Fig. 3)</td>
                        <td align="left" rowspan="1" colspan="1">(25–27)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>Abbreviations: HSC, hematopoietic stem cells; RRM1, ribonucleotide reductase catalytic subunit M1; TYMS, thymidylate synthase.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec1-2">
                <title>Principles of HMA dose and schedule selection</title>
                <sec id="sec1-2-1">
                  <title>Dose selection</title>
                  <p>The earliest trials of azacitidine were based on conventional oncotherapy objectives of apoptosis/cytotoxicity, because high concentrations of azacitidine or decitabine do cause nucleotide imbalances, damage DNA, and can thereby activate p53/apoptosis (<xref rid="fig1" ref-type="fig">Fig. 1</xref>; <xref rid="tbl1" ref-type="table">Table 1</xref>). Doses were therefore based on MTDs (<xref rid="bib16" ref-type="bibr">16</xref>; reviewed in ref. <xref rid="bib17" ref-type="bibr">17</xref>). These trials were unsuccessful. DNMT1 targeting, however, is achieved and saturated at relatively low azacitidine concentrations (<xref rid="fig1" ref-type="fig">Fig. 1</xref>), and 10-fold reductions from initially evaluated doses produced clinical success. Standard azacitidine regimens today administer 50–75 mg/m<sup>2</sup>/d (<xref rid="bib17" ref-type="bibr">17</xref>). Decitabine clinical development was similar. Initial, unsuccessful trials administered daily doses as high as 600 mg/m<sup>2</sup> (<xref rid="bib17" ref-type="bibr">17</xref>); the first approval used a &gt;10-fold lower dose of 45 mg/m<sup>2</sup>, and a second-approved regimen uses an even lower dose of 20 mg/m<sup>2</sup>/d (<xref rid="bib18" ref-type="bibr">18, 19</xref>). These dose reductions were arrived at empirically, therefore, we conducted studies to formally identify minimum decitabine doses needed to deplete DNMT1 without cytotoxicity to normal bone marrow/HSPC in non-human primates and humans: 0.1–0.2 mg/kg/d (∼5 mg/m<sup>2</sup>/d; refs. <xref rid="bib2" ref-type="bibr">2, 20, 21</xref>).</p>
                </sec>
                <sec id="sec1-2-2">
                  <title>Schedule selection</title>
                  <p>In the earliest HMA trials, cytotoxic daily doses could only be tolerably administered for a few days, for example, 3 days, followed by intervals of approximately 6 weeks needed to recover from the cytotoxic side-effects (schedules were necessarily pulse-cycled). One benefit of dose reductions that decreased cytotoxicity was that intervals between treatment pulses could be shortened. Standard azacitidine regimens administer 50–75 mg/m<sup>2</sup>/d for 7–10 days every 4 weeks; the most commonly used standard regimen of decitabine administers 20 mg/m<sup>2</sup>/d for 5 days every 4 weeks. This more frequent administration is beneficial because DNMT1 targeting by azacitidine or decitabine requires overlap between treatment exposure windows and malignant cell S-phase entries. That is, DNMT1 targeting is S-phase or exposure time dependent, and lowering the decitabine dose from 45 to 20 mg/m<sup>2</sup>/d, and increasing the frequency of administration from 3 days every 6 weeks to 5 days every 4 weeks produced 2–3-fold improvements in remission and hematologic improvement rates (<xref rid="bib18" ref-type="bibr">18, 19</xref>). Building on this logical progression, we scheduled non-cytotoxic, DNMT1-depleting doses of decitabine 0.1–0.2 mg/kg/d (∼5 mg/m<sup>2</sup>/d) for frequent and distributed administration 1–2X/week. The overall response rate (ORR) per International Working Group criteria was 44%, including complete cytogenetic remissions of <italic toggle="yes">TP53</italic>-mutated disease containing complex cytogenetic abnormalities (<xref rid="bib2" ref-type="bibr">2, 12, 22</xref>). This non-cytotoxic regimen has been effectively and safely administered for &gt;5 years in patients with MDS &gt;80 years old (<xref rid="bib12" ref-type="bibr">12</xref>).</p>
                  <p>Thus, pulse-cycled schedules of HMA administration reflect conventions inherited from cytotoxic treatments. Lower doses that target DNMT1 without cytotoxicity enable alternative schedules of administration that increase drug exposure durations and distributions to increase S-phase–dependent DNMT1 targeting.</p>
                </sec>
              </sec>
              <sec id="sec1-3">
                <title>Successful HMA combinations: Lessons learned</title>
                <p>HMAs can produce non-toxic clinical responses but relapse/resistance is routine. Resistance, <italic toggle="yes">in vitro</italic>, in mice and in patients, is characterized by failure to deplete DNMT1 (<xref rid="bib23" ref-type="bibr">23, 24</xref>). To deplete DNMT1, azacitidine, a cytidine analog, and decitabine, a deoxycytidine analog, must be processed by pyrimidine metabolism into a nucleotide analog that incorporates into the newly synthesized DNA strand during S-phase (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Pyrimidine metabolism is a network evolved for nucleotide homeostasis. The interactions between decitabine and azacitidine and this network perturb nucleotide balances, and thus trigger automatic, balancing responses that dampen decitabine or azacitidine pro-drug processing into DNMT1-depleting nucleotide (<xref rid="fig2" ref-type="fig">Fig. 2</xref>; ref. <xref rid="bib23" ref-type="bibr">23</xref>). One key pyrimidine metabolism adaptation underlying this mode of resistance is upregulated <italic toggle="yes">de novo</italic> pyrimidine synthesis, which competes directly with the DNMT1-depleting nucleotide Aza-dCTP by building natural cytidines and deoxycytidines from amino acid building blocks (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). Inhibiting <italic toggle="yes">de novo</italic> pyrimidine synthesis can thus restore AML cell sensitivity to HMAs (<xref rid="bib14" ref-type="bibr">14, 15</xref>). Venetoclax is a BCL2 inhibitor that dislodges from BCL2 sequestration BH3-only proteins; BH3-only proteins then bind to and enable the effector proteins BAX and BAK1 to permeabilize mitochondrial membranes (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). This depowers mitochondrial processes, including <italic toggle="yes">de novo</italic> pyrimidine synthesis (<xref rid="fig3" ref-type="fig">Fig. 3</xref>; ref. <xref rid="bib25" ref-type="bibr">25</xref>). Also decreased are mitochondrial outputs of nicotinamide adenine dinucleotide (NAD<sup>+</sup>/NADH) and flavin adenine dinucleotide (FAD<sup>+</sup>/FADH), mandatory cofactors for the transcription repressing enzymes C-terminal binding protein 1 (CTBP1), and lysine demethylase 1A (KDM1A), that like DNMT1, are implicated in oncogenic, aberrant epigenetic repression of hundreds of lineage-differentiation genes in oncogenesis (<xref rid="fig3" ref-type="fig">Fig. 3</xref>; refs. <xref rid="bib15" ref-type="bibr">15, 25–27</xref>). Thus, successful mitochondrial membrane depolarization by venetoclax, short of triggering full-blown apoptosis, can augment DNMT1 targeting/terminal differentiation in several ways (<xref rid="fig3" ref-type="fig">Fig. 3</xref>).</p>
                <fig position="float" id="fig3">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Mechanisms by which mitochondrial targeting by venetoclax may cooperate with DNMT1 targeting by Aza-dCTP. <bold>A,</bold> <italic toggle="yes">De novo</italic> pyrimidine synthesis manufactures dCTP that competes with Aza-dCTP, and requires the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), powered by the membrane electron gradient. Also powered this way are mitochondrial outputs of epigenetic enzyme cofactors, that <italic toggle="yes">similar to DNMT1</italic>, <italic toggle="yes">inhibit terminal differentiation of malignant cells</italic> (Ac-CoA, acetyl-CoA; AKG, alpha-ketoglutarate; CTBP1, C-terminal binding protein 1 corepressor; CTP, cytidine triphosphate; dCTP, deoxycytidine triphosphate; FAD, flavin adenine dinucleotide; HAT, histone acetyltransferase; KDM1, lysine demethylase 1; NAD, nicotinamide adenine dinucleotide; TET, ten-eleven translocation methylcytosine dioxygenases). <bold>B,</bold> The antiapoptotic BCL2 protein family (BCL2, BCL2L2, BCL2L1, and MCL1) sequester BH3-only proteins (BID, BAD, etc.) that otherwise activate the effector proteins BAX and BAK1 that permeabilize mitochondrial membranes. <bold>C,</bold> BAX, a key effector protein in the pathway downstream of venetoclax, is significantly decreased in primary AML cells containing mutated or deleted <italic toggle="yes">TP53</italic>. Mean±SD. TCGA RNA-Seq, <italic toggle="yes">n</italic> = 167; <italic toggle="yes">P</italic> value two-sided <italic toggle="yes">t</italic> test. <bold>D,</bold> This observation is recapitulated in hematopoietic malignancy cell lines. CCLE RNA-Seq, <italic toggle="yes">n</italic> = 175.</p>
                  </caption>
                  <alt-text>Figure 3. Mechanisms by which mitochondrial targeting by venetoclax may cooperate with DNMT1 targeting by Aza-dCTP. A, De novo pyrimidine synthesis manufactures dCTP that competes with Aza-dCTP, and requires the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), powered by the membrane electron gradient. Also powered this way are mitochondrial outputs of epigenetic enzyme cofactors, that similar to DNMT1, inhibit terminal differentiation of malignant cells (Ac-CoA, acetyl-CoA; AKG, alpha-ketoglutarate; CTBP1, C-terminal binding protein 1 corepressor; CTP, cytidine triphosphate; dCTP, deoxycytidine triphosphate; FAD, flavin adenine dinucleotide; HAT, histone acetyltransferase; KDM1, lysine demethylase 1; NAD, nicotinamide adenine dinucleotide; TET, ten-eleven translocation methylcytosine dioxygenases). B, The antiapoptotic BCL2 protein family (BCL2, BCL2L2, BCL2L1, and MCL1) sequester BH3-only proteins (BID, BAD, etc.) that otherwise activate the effector proteins BAX and BAK1 that permeabilize mitochondrial membranes. C, BAX, a key effector protein in the pathway downstream of venetoclax, is significantly decreased in primary AML cells containing mutated or deleted TP53. Mean±SD. TCGA RNA-Seq, n = 167; P value two-sided t test. D, This observation is recapitulated in hematopoietic malignancy cell lines. CCLE RNA-Seq, n = 175.</alt-text>
                  <graphic xlink:href="6653fig3" position="float"/>
                </fig>
                <p>Other cofactors produced by mitochondria, for example, alpha-ketoglutarate (AKG), serve epigenetic enzymes that promote terminal differentiation, for example, ten-eleven translocation 2 (TET2) that demethylates DNA (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). AKG is antagonized by an oncometabolite 2-hydroxyglutarate (2HG) that is produced by mutant IDH1 or IDH2 (<italic toggle="yes">IDH1</italic> and <italic toggle="yes">IDH2</italic> mutations are recurrent in myeloid malignancies). Accordingly, inhibitors of mutant IDH1/2 align with therapeutic index/pathway goals of HMA therapy, and early clinical trial data for such combinations are encouraging (<xref rid="fig3" ref-type="fig">Fig. 3</xref>).</p>
                <p>The pyrimidine metabolism enzyme, cytidine deaminase (CDA), rapidly catabolizes azacitidine and decitabine into uridine counterparts that do not target DNMT1, and also contributes to HMA resistance (<xref rid="fig2" ref-type="fig">Fig. 2</xref>; ref. <xref rid="bib23" ref-type="bibr">23</xref>). CDA in the liver and gastrointestinal tract moreover severely limits HMA plasma half-life and oral bioavailability (<xref rid="bib28" ref-type="bibr">28, 29</xref>). A fixed-dose co-formulation of the CDA inhibitor cedazuridine with oral decitabine was recently approved for MDS treatment in the United States based on pharmacokinetic equivalence to parenteral decitabine (<xref rid="bib30" ref-type="bibr">30</xref>). Another CDA inhibitor, tetrahydrouridine, has also been co-formulated with oral decitabine and 5-azacytidine, with weight-based dosing and schedules of administration designed for non-cytotoxic DNMT1 targeting (<xref rid="bib28" ref-type="bibr">28, 31, 32</xref>).</p>
                <p>Clinical trial experience thus suggests utility in combining HMAs with agents aiming to manipulate pyrimidine and mitochondrial metabolism, to thereby enhance pro-drug processing and non-cytotoxic corepressor targeting, with open opportunities to refine and optimize such combinations.</p>
              </sec>
              <sec id="sec1-4">
                <title>Unsuccessful RCTs of combination therapy: Lessons learned</title>
                <p>We analyzed nine completed, unsuccessful, combination RCTs (<xref rid="tbl2" ref-type="table">Table 2</xref>) and identified departures from, and workable design modifications to better align with the mechanism and pathway principles learned thus far, to in this way inform future efforts.</p>
                <table-wrap position="float" id="tbl2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Randomized clinical trials of HMA combination therapy to treat MDS/AML—results.</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">#</th>
                        <th align="left" rowspan="1" colspan="1">Arms, Clinical Trial#</th>
                        <th align="left" rowspan="1" colspan="1">Patients</th>
                        <th align="left" rowspan="1" colspan="1">Schedule (28-day cycles)</th>
                        <th align="left" rowspan="1" colspan="1">Phase II/III results</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Entinostat vs.</td>
                        <td align="left" rowspan="1" colspan="1">97 MDS</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: HN (CR + PR + HI)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza alone</td>
                        <td align="left" rowspan="1" colspan="1">52 AML</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT00313586</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-10</td>
                        <td align="left" rowspan="1" colspan="1">Aza: HN 32% (95% CI, 22%–44%), median OS 18 mo</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Entinostat</bold> D3 and 10</td>
                        <td align="left" rowspan="1" colspan="1">Combination: HN 27% (95% CI, 17%–39%), median OS 13 mo</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Pracinostat vs.</td>
                        <td align="left" rowspan="1" colspan="1">102 MDS IPSS Int. or high risk</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: CR by cycle 6</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza + Placebo</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-7 or D1-5</td>
                        <td align="left" rowspan="1" colspan="1">Aza: CR 18%, median OS 16 mo</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT01873703</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Pracinostat</bold> QOD D1-21</td>
                        <td align="left" rowspan="1" colspan="1">Combination: CR 33% (<italic toggle="yes">P</italic> = 0.07), median OS 19 mo (HR, 1.21; 95% CI, 0.66–2.23)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Pracinostat vs.</td>
                        <td align="left" rowspan="1" colspan="1">500 ΑML ineligible for standard induction</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: OS</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza + Placebo</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-7</td>
                        <td align="left" rowspan="1" colspan="1">Terminated prematurely because unlikely to meet 1<sup>o</sup> End-point</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT03151408</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Pracinostat</bold> QOD or 3X/wk D1-21</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Vorinostat vs.</td>
                        <td align="left" rowspan="1" colspan="1">217 AML</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: ORR and OS</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza: ORR 41%, CR/CRi/mCR 22%, median OS 9.6 mo</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Combination: ORR 42%, CR/CRi/mCR 26%, median OS 11.0 mo (HR, 1.15; 95% CI, 0.87–1.51; <italic toggle="yes">P</italic> = 0.32)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">42 MDS</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza alone NCT01617226</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-7</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Vorinostat</bold> D3-9</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">Dec + Valproate vs.</td>
                        <td align="left" rowspan="1" colspan="1">87 MDS R-IPSS</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: ORR</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Dec alone</td>
                        <td align="left" rowspan="1" colspan="1">Int. or high risk</td>
                        <td align="left" rowspan="1" colspan="1"><bold>Dec</bold> D1-5</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT0l305499</td>
                        <td align="left" rowspan="1" colspan="1">62 AML ≥60-y-old</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Valproate</bold> D1-7</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Dec: CR 31%, ORR 51%, median OS 11.9 mo</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Combination: CR 37% (<italic toggle="yes">P</italic> = 0.49), ORR 58% (<italic toggle="yes">P</italic> = 0.41), median OS 11.2 mo (<italic toggle="yes">P</italic> = 0.92)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Lenalidomide vs.</td>
                        <td align="left" rowspan="1" colspan="1">224 MDS IPSS</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: ORR</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza + Vorinostat vs.</td>
                        <td align="left" rowspan="1" colspan="1">high risk</td>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-7</td>
                        <td align="left" rowspan="1" colspan="1">Aza: 38%, median OS 15 mo</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza alone</td>
                        <td align="left" rowspan="1" colspan="1">53 CMML</td>
                        <td align="left" rowspan="1" colspan="1"><bold>Lenalidomide</bold> D1-21</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Lenalidomide: 49% (<italic toggle="yes">P</italic> = 0.14), median OS 19 mo (<italic toggle="yes">P</italic> = 0.68)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT01522976</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Vorinostat</bold> D3-9</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Vorinostat: 27% (<italic toggle="yes">P</italic> = 0.16), median OS 17 mo (<italic toggle="yes">P</italic> = 0.22)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Gilteritinib vs.</td>
                        <td align="left" rowspan="1" colspan="1">114 AML ineligible for standard induction</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: OS</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza alone</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-7</td>
                        <td align="left" rowspan="1" colspan="1">Terminated prematurely because unlikely to meet primary endpoint</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT02752035</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Gilteritinib</bold> D1-28</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Eprenetapopt vs.</td>
                        <td align="left" rowspan="1" colspan="1">154 MDS, TP53 mutant</td>
                        <td align="left" rowspan="1" colspan="1">Sequential:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: CR</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza alone</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D4-10 or D4-5 + D8-12</td>
                        <td align="left" rowspan="1" colspan="1">Aza: CR 22.4%</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT03745716</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Eprenetapopt</bold> D1-4</td>
                        <td align="left" rowspan="1" colspan="1">Combination: CR 33.3% (<italic toggle="yes">P</italic> = 0.13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Terminated prematurely because unlikely to meet primary endpoint.</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">9</td>
                        <td align="left" rowspan="1" colspan="1">Aza + Eltrombopag vs.</td>
                        <td align="left" rowspan="1" colspan="1">356 MDS with thrombocytopenia</td>
                        <td align="left" rowspan="1" colspan="1">Concurrent:</td>
                        <td align="left" rowspan="1" colspan="1"><italic toggle="yes">1<sup>o</sup> End-point</italic>: Platelet-transfusion freedom in cycles 1–4</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Aza + Placebo</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Aza</bold> D1-7</td>
                        <td align="left" rowspan="1" colspan="1">Aza: ORR 35%, median OS 78 weeks</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">NCT02158936</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"><bold>Eltrombopag</bold> daily D1-28</td>
                        <td align="left" rowspan="1" colspan="1">Combination: ORR 20% (<italic toggle="yes">P</italic> = 0.005), median OS 60 weeks</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>Abbreviations: AML, acute myeloid leukemia; Aza, azacitidine; CMML, chronic myelomonocytic leukemia; CR, complete remission; CRi, CR with incomplete blood count recovery; D, Day; Dec, decitabine; HI, hematologic improvement; HN, hematologic normalization; HR, hazard ratio; Int, intermediate; mCR, marrow CR; MDS, myelodysplastic syndromes; mo, months; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial remission; R-IPSS, Revised International Prognostic Scoring System.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="sec1-4-1">
                  <title>HMA combinations with histone deacetylase inhibitors</title>
                  <p>Histone deacetylase inhibitors (HDACi), by promoting acetylation of histones and other proteins, can also target the epigenome to reverse oncogenic gene silencing. HMA combination with HDACis was found synergistic in preclinical studies, and produced high response rates in small, single-arm studies (<xref rid="bib33" ref-type="bibr">33</xref>). Entinostat is a potent oral inhibitor of HDAC class I and was combined with azacitidine in the E1905 RCT in patients with MDS and AML with myelodysplasia-related changes (<xref rid="bib34" ref-type="bibr">34</xref>). Azacitidine alone was favored with hematologic normalization (HN) in 32% versus 27% for the combination (<xref rid="tbl2" ref-type="table">Table 2</xref>). Pracinostat is a class I/II/IV HDACi and was combined with azacitidine in an RCT in patients with International Prognostic Scoring System (IPSS) intermediate (INT)-2 or high-risk MDS (<xref rid="bib35" ref-type="bibr">35</xref>). The combination did not provide a significant ORR or OS benefit versus azacitidine plus placebo (<xref rid="tbl2" ref-type="table">Table 2</xref>). Recently, an RCT of pracinostat plus azacitidine versus placebo plus azacitidine in patients with AML was terminated prematurely, due to failure to meet its primary endpoint of complete remission (CR) rate superiority (<xref rid="bib36" ref-type="bibr">36</xref>). Vorinostat is an HDAC class I/II inhibitor; multicenter open-label RCT compared vorinostat plus azacitidine versus azacitidine monotherapy in patients with newly diagnosed or relapsed/refractory AML or IPSS INT-2 or high-risk MDS (<xref rid="bib37" ref-type="bibr">37</xref>). Unfortunately, this trial also failed to meet its ORR and OS primary endpoints. Valproic acid is a pan-HDAC inhibitor (<xref rid="bib38" ref-type="bibr">38</xref>); an RCT evaluation of valproic acid plus decitabine versus decitabine alone in INT or high-risk patients with MDS and AML older than 60 failed to demonstrate significant ORR or OS benefit for the combination (<xref rid="tbl2" ref-type="table">Table 2</xref>; ref. <xref rid="bib39" ref-type="bibr">39</xref>). Finally, SWOG-S1117 randomized patients with higher-risk MDS (81%) or chronic myelomonocytic leukemia (CMML; 19%) into three arms: azacitidine plus lenalidomide versus azacitidine plus vorinostat versus azacitidine monotherapy (<xref rid="bib40" ref-type="bibr">40</xref>). No significant improvement in the ORR primary endpoint was observed between either combination arm versus azacitidine monotherapy (<xref rid="tbl2" ref-type="table">Table 2</xref>). An ORR difference was observed in subset analyses of patients with CMML, favoring azacitidine plus lenalidomide (ORR 68%, <italic toggle="yes">n</italic> = 19) over azacitidine alone (ORR 28%, <italic toggle="yes">n</italic> = 18; <italic toggle="yes">P</italic> = 0.02), but without a difference in OS (<italic toggle="yes">P</italic> = 0.87). On the basis of the overall non-superior ORR and OS outcomes, the phase III part of the study was not conducted.</p>
                </sec>
                <sec id="sec1-4-2">
                  <title>HMA combinations with other targeted agents</title>
                  <p>HMAs have also been combined with drugs targeting mutant FMS-like tyrosine kinase 3 (FLT3) or mutant p53, and with thrombopoietin (TPO)-receptor agonists. Again, single-arm trial results were encouraging, but not RCT readouts. <italic toggle="yes">FLT3</italic> is among the most recurrently mutated genes in AML and encodes for a transmembrane ligand–activated receptor. Gilteritinib is a potent second-generation FLT3 inhibitor active against both <italic toggle="yes">FLT3</italic> internal tandem duplication and <italic toggle="yes">FLT3</italic> tyrosine kinase domain mutations. Several RCTs have failed to demonstrate superiority of FLT3 inhibitors combined with HMAs versus HMAs alone; most recently, the phase III, multicenter, open-label LACEWING RCT compared gilteritinib plus azacitidine to azacitidine alone in patients with newly diagnosed <italic toggle="yes">FLT3</italic>-mutated AML ineligible for induction chemotherapy. Although the phase I–II results looked promising, the phase III failed to meet its primary endpoint—there was no OS benefit (<xref rid="tbl2" ref-type="table">Table 2</xref>; ref. <xref rid="bib41" ref-type="bibr">41</xref>).</p>
                  <p><italic toggle="yes">TP53</italic> mutations in MDS or AML predict poor prognoses, and a small molecule, APR-246 (eprenetapopt), has been postulated to convert the mutant-p53 protein to its original wild-type form. In RCT evaluation, patients with <italic toggle="yes">TP53</italic>-mutated MDS received APR-246 plus azacitidine versus azacitidine alone. Again, phase IB/II results were encouraging but phase III failed to show significantly higher CR rate for the combination versus azacitidine alone (<xref rid="tbl2" ref-type="table">Table 2</xref>; ref. <xref rid="bib42" ref-type="bibr">42</xref>). Insofar as azacitidine/decitabine success to treat MDS/AML is because of a p53-independent mechanism-of-action, it may be more rational to combine this class of agent (p53 stabilizer) with agents intending p53-dependent cytotoxicity, for example, cytarabine (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).</p>
                  <p>Thrombocytopenia in patients with MDS/AML is a major source of morbidity, and single-agent TPO-receptor agonists have shown efficacy in raising platelet counts. A double-blind RCT-assigned IPSS INT-1, INT-2, and high-risk patients with MDS with baseline platelet count less than 75 × 10<sup>9</sup>/L to eltrombopag plus azacitidine versus placebo plus azacitidine (<xref rid="bib43" ref-type="bibr">43</xref>). The study ended prematurely because it did not meet its primary endpoint of platelet-transfusion independency, and there was no significant improvement in ORR or OS with the combination (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p>
                </sec>
                <sec id="sec1-4-3">
                  <title>Why did these RCTs fail?</title>
                  <p>These combinations did not add benefit and sometimes demonstrated worse responses than with HMAs alone (<xref rid="bib34" ref-type="bibr">34, 40</xref>). Here are reasons:</p>
                  <list list-type="simple">
                    <list-item>
                      <p>(i) <italic toggle="yes">Direct antagonism of S-phase</italic>–<italic toggle="yes">dependent HMA by concurrent administration of cytostatic</italic>/<italic toggle="yes">cytotoxic investigational agent</italic>. A common attribute of these RCTs is that the investigational agents can have cytostatic effects—even eltrombopag has cytostatic effects on leukemia cells (<xref rid="bib44" ref-type="bibr">44, 45</xref>)—and were given concurrently/overlapping with the HMA (<xref rid="tbl2" ref-type="table">Table 2</xref>). Such scheduling has the potential to antagonize the mainstay HMAs, for example, correlative analysis of DNA methylation showed that combination entinostat plus azacitidine produced less demethylation than the azacitidine-alone arm (<xref rid="bib34" ref-type="bibr">34</xref>). It would be reasonable, therefore, to <italic toggle="yes">avoid concurrent (</italic>same day) <italic toggle="yes">scheduling of less active agents that have cytostatic effects</italic>, <italic toggle="yes">including HDACi</italic>, <italic toggle="yes">immunomodulatory imide drugs (IMiD)</italic>, <italic toggle="yes">or kinase inhibitors</italic>, <italic toggle="yes">with the HMA backbone</italic>, <italic toggle="yes">because this would antagonize S-phase–dependent DNMT1 depletion</italic> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p>
                    </list-item>
                    <list-item>
                      <p>(ii) <italic toggle="yes">Investigational agent suppression of functional myelopoiesis</italic>. Known side-effects of HDACi as single agents, even in patients without myeloid malignancies, are thrombocytopenia, neutropenia, and anemia (<xref rid="bib40" ref-type="bibr">40</xref>). Such myelosuppression may delay or decrease feasible exposure times to the more active HMA. How often an HMA is administered dictates the fraction of the malignant cell population that has the possibility of being treated because DNMT1 targeting is S-phase dependent. In successful RCT evaluations of azacitidine plus venetoclax, low blood counts attributed to therapy were managed by reducing venetoclax frequency and/or dose (<xref rid="bib46" ref-type="bibr">46</xref>). By contrast, in other RCTs, myelosuppression was managed by reducing azacitidine frequency and dose, even discontinuing azacitidine altogether, favoring continuation of investigational agents shown to be less active as single agents (<xref rid="bib40" ref-type="bibr">40</xref>). Thus, <italic toggle="yes">myelosuppression attributed to treatment should be managed as much as possible with dose and/or frequency reductions of the less-active investigational agent</italic>, <italic toggle="yes">not the HMA</italic>.</p>
                    </list-item>
                    <list-item>
                      <p>(iii) <italic toggle="yes">Destruction of normal HSPC</italic> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>; <xref rid="tbl1" ref-type="table">Table 1</xref>). Separation of epigenetic pharmacodynamic effects that terminate malignant self-replications, from cytotoxic effects that destroy normal HSPC, has been shown for HMA but not for HDACi (<xref rid="bib47" ref-type="bibr">47–50</xref>). This could be because HDACs have pleotropic cell physiology functions, not restricted to epigenetic repression of genes (HDAC deacetylate substrates other than histones; refs. <xref rid="bib47" ref-type="bibr">47–50</xref>). HDACis thus have significant side-effects but modest activity for treating myeloid malignancies (reviewed in ref. <xref rid="bib33" ref-type="bibr">33</xref>). If biochemically possible, it would be useful to design, identify, and use doses of the HDACi that inhibits HDAC, or the IMiD that alters cereblon substrate specificity, or the kinase inhibitor to inhibit FLT3, without cytotoxicity to normal HSPC (dosage selection based on pharmacodynamics instead of maximum-tolerated levels). <italic toggle="yes">Investigational agent dose</italic>, <italic toggle="yes">as per the HMA</italic>, <italic toggle="yes">should be selected per molecular-targeted pharmacodynamic (“optimal-biological-dose”) not MTD principles</italic>, <italic toggle="yes">to limit or avoid indiscriminate antimetabolite effects and cytotoxicity to normal HSPC needed for response and durable benefit</italic>.</p>
                    </list-item>
                    <list-item>
                      <p>(iv) <italic toggle="yes">Fidelity to schedules of administration</italic>. Non-superiority with investigational agent addition to HMAs in RCTs implies the HMA backbone also largely accounts for preceding phase II results that were found exciting. One reason for apparently better results than historic for the same HMA regimen could be fidelity to schedules-of-administration, important for S-phase–dependent DNMT1 targeting. In one phase II evaluation of decitabine 20 mg/m<sup>2</sup>/d for 5 days every 28 days, growth factor support was used to alleviate neutropenia that might otherwise threaten on-time administration of cycles every 28 days (<xref rid="bib18" ref-type="bibr">18, 19</xref>), whereas in another phase II evaluation of the same regimen, neutropenia was managed by cycle delays (<xref rid="bib19" ref-type="bibr">19</xref>); the trial pursuing <italic toggle="yes">on-time HMA administration</italic> reported ORRs of 63% versus 35% for the trial using cycle delays (<xref rid="fig1" ref-type="fig">Fig. 1</xref>; <xref rid="tbl1" ref-type="table">Table 1</xref>; refs. <xref rid="bib18" ref-type="bibr">18, 19</xref>). Hence, <italic toggle="yes">it could be useful to consider growth factor support</italic>, <italic toggle="yes">or other measures</italic>, <italic toggle="yes">to enable on-time administration of the HMA; avoid cycle delays</italic> (<xref rid="bib17" ref-type="bibr">17</xref>).</p>
                    </list-item>
                  </list>
                  <p>Another observation is lower response rates for the same combination treatment in phase III versus prior phase II, for example, eprepranocept + azacitidine produced a CR rate of 33.3% in the phase III RCT (<italic toggle="yes">n</italic> = 77) but 50% in the prior single-arm phase II (<italic toggle="yes">n</italic> = 40; ref. <xref rid="bib42" ref-type="bibr">42</xref>). A straightforward explanation is less selected and larger (more representative) sample sizes in phase III.</p>
                </sec>
              </sec>
            </sec>
            <sec id="sec2">
              <title>Conclusion</title>
              <p>In sum, &gt;40 years of clinical trial evidence, complemented by mechanism studies, suggests selecting HMA dose and schedule to increase S-phase–dependent DNMT1 targeting, manipulating pyrimidine metabolism to increase HMA pro-drug processing into DNMT1-depleting nucleotide, and targeting of other epigenetic enzymes implicated in oncogenic repression of lineage-maturation programs, all the while adhering to basic therapeutic index principles that are especially critical when treating myeloid malignancies in the elderly.</p>
            </sec>
            <sec id="sec3">
              <title>Authors' Disclosures</title>
              <p>A. Shastri reports other support from Kymera Therapeutics and OncLive, as well as personal fees from Janssen Pharmaceuticals outside the submitted work. A.K. Verma reports grants from BMS, Janssen, Curis, and Prelude, as well as other support from Stelexis during the conduct of the study. Y. Saunthararajah reports other support from EpiDestiny and Novo Nordisk during the conduct of the study. In addition, Y. Saunthararajah has a patent for tetrahydrouridine and decitabine issued, licensed, and with royalties paid from EpiDestiny; has a patent for tetrahydrouridine and 5-azacytidine pending; has a patent for ISWI inhibitor (tumor differentiation therapy) issued; is in research and development of drug strategies for non-cytotoxic targeting of epigenetic proteins, defining how to combine tetrahydrouridine, decitabine, and 5-azacytidine; is leading a team that is developing a non-cytotoxic inhibitor of the ISWI family of ATP-dependent chromatin remodelers; and reports patents and industry partnerships in this field of research and development. No disclosures were reported by the other authors.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>This work was supported by the National Heart, Lung and Blood Institute PO1 HL146372, National Cancer Institute P30 CA043703, National Cancer Institute RO1 CA204373, Robert and Jennifer McNeil, Lescek and Jolanta Czarnecki, and Dane and Louise Miller (to Y Saunthararajah). This work was also supported by National Heart, Lung and Blood Institute R01HL139487 and R01HL150832, Albert Einstein Cancer Center Support grant (P30CA013330), Evans MDS grant, and V Foundation for Cancer Research (to A.K. Verma).</p>
              <p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked <italic toggle="yes">advertisement</italic> in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Velcheti</surname> <given-names>V</given-names></string-name>, <string-name><surname>Schrump</surname> <given-names>D</given-names></string-name>, <string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Ultimate precision: targeting cancer but not normal self-replication</article-title>. <source>Am Soc Clin Oncol Educ Book</source> <year>2018</year>;<volume>38</volume>:<fpage>950</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">30231326</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sekeres</surname> <given-names>M</given-names></string-name>, <string-name><surname>Advani</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Durkin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Radivoyevitch</surname> <given-names>T</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes</article-title>. <source>J Clin Invest</source> <year>2015</year>;<volume>125</volume>:<fpage>1043</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">25621498</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ng</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Ebrahem</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Negrotto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>RZ</given-names></string-name>, <string-name><surname>Link</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Z</given-names></string-name>, <etal>et al</etal></person-group> <article-title>p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia</article-title>. <source>Leukemia</source> <year>2011</year>;<volume>25</volume>:<fpage>1739</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">21701495</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wattel</surname> <given-names>E</given-names></string-name>, <string-name><surname>Preudhomme</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hecquet</surname> <given-names>B</given-names></string-name>, <string-name><surname>Vanrumbeke</surname> <given-names>M</given-names></string-name>, <string-name><surname>Quesnel</surname> <given-names>B</given-names></string-name>, <string-name><surname>Dervite</surname> <given-names>I</given-names></string-name>, <etal>et al</etal></person-group> <article-title>p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies</article-title>. <source>Blood</source> <year>1994</year>;<volume>84</volume>:<fpage>3148</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">7949187</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Negrotto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Jankowska</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Bodo</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gopalan</surname> <given-names>B</given-names></string-name>, <string-name><surname>Guinta</surname> <given-names>K</given-names></string-name>, <etal>et al</etal></person-group> <article-title>CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors</article-title>. <source>Leukemia</source> <year>2012</year>;<volume>26</volume>:<fpage>244</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">21836612</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Haan</surname> <given-names>G</given-names></string-name>, <string-name><surname>Lazare</surname> <given-names>SS</given-names></string-name></person-group>. <article-title>Aging of hematopoietic stem cells</article-title>. <source>Blood</source> <year>2018</year>;<volume>131</volume>:<fpage>479</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">29141947</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trowbridge</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Sinha</surname> <given-names>AU</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>N</given-names></string-name>, <string-name><surname>Li</surname> <given-names>M</given-names></string-name>, <string-name><surname>Armstrong</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Orkin</surname> <given-names>SH</given-names></string-name></person-group>. <article-title>Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains</article-title>. <source>Genes Dev</source> <year>2012</year>;<volume>26</volume>:<fpage>344</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">22345515</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Broske</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Vockentanz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kharazi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huska</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Mancini</surname> <given-names>E</given-names></string-name>, <string-name><surname>Scheller</surname> <given-names>M</given-names></string-name>, <etal>et al</etal></person-group> <article-title>DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction</article-title>. <source>Nat Genet</source> <year>2009</year>;<volume>41</volume>:<fpage>1207</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">19801979</pub-id></mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Negrotto</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Ebrahem</surname> <given-names>Q</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus</article-title>. <source>Mol Cancer Ther</source> <year>2010</year>;<volume>9</volume>:<fpage>1536</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">20501800</pub-id></mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Milhem</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mahmud</surname> <given-names>N</given-names></string-name>, <string-name><surname>Lavelle</surname> <given-names>D</given-names></string-name>, <string-name><surname>Araki</surname> <given-names>H</given-names></string-name>, <string-name><surname>DeSimone</surname> <given-names>J</given-names></string-name>, <string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Modification of hematopoietic stem cell fate by 5aza 2′ deoxycytidine and trichostatin A</article-title>. <source>Blood</source> <year>2004</year>;<volume>103</volume>:<fpage>4102</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">14976039</pub-id></mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dohner</surname> <given-names>H</given-names></string-name>, <string-name><surname>Dolnik</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Seymour</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Minden</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>RM</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care</article-title>. <source>Leukemia</source> <year>2018</year>;<volume>32</volume>:<fpage>2546</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">30275526</pub-id></mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Awada</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>RZ</given-names></string-name>, <string-name><surname>Kishtagari</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kuzmanovic</surname> <given-names>T</given-names></string-name>, <string-name><surname>Durrani</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kerr</surname> <given-names>CM</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies</article-title>. <source>Br J Haematol</source> <year>2020</year>;<volume>188</volume>:<fpage>924</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">31736067</pub-id></mixed-citation>
              </ref>
              <ref id="bib13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Welch</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Petti</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Fronick</surname> <given-names>CC</given-names></string-name>, <string-name><surname>O'Laughlin</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fulton</surname> <given-names>RS</given-names></string-name>, <etal>et al</etal></person-group> <article-title>TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes</article-title>. <source>N Engl J Med</source> <year>2016</year>;<volume>375</volume>:<fpage>2023</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">27959731</pub-id></mixed-citation>
              </ref>
              <ref id="bib14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kayamori</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhong</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kaito</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shinoda</surname> <given-names>D</given-names></string-name>, <string-name><surname>Koide</surname> <given-names>S</given-names></string-name>, <etal>et al</etal></person-group> <article-title>DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes</article-title>. <source>Blood Adv</source> <year>2021</year>;<volume>5</volume>:<fpage>438</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">33496740</pub-id></mixed-citation>
              </ref>
              <ref id="bib15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation</article-title>. <source>Haematologica</source> <year>2020</year>;<volume>105</volume>:<fpage>2191</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">33054042</pub-id></mixed-citation>
              </ref>
              <ref id="bib16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saiki</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Bodey</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Hewlett</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Amare</surname> <given-names>M</given-names></string-name>, <string-name><surname>Morrison</surname> <given-names>FS</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>HE</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study</article-title>. <source>Cancer</source> <year>1981</year>;<volume>47</volume>:<fpage>1739</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">6164472</pub-id></mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <year>2013</year>;<volume>2013</volume>:<fpage>511</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">24319226</pub-id></mixed-citation>
              </ref>
              <ref id="bib18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kantarjian</surname> <given-names>HM</given-names></string-name>, <string-name><surname>O'Brien</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ravandi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Cortes</surname> <given-names>J</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience</article-title>. <source>Cancer</source> <year>2007</year>;<volume>109</volume>:<fpage>1133</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">17315156</pub-id></mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Steensma</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Baer</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Slack</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Buckstein</surname> <given-names>R</given-names></string-name>, <string-name><surname>Godley</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial</article-title>. <source>J Clin Oncol</source> <year>2009</year>;<volume>27</volume>:<fpage>3842</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">19528372</pub-id></mixed-citation>
              </ref>
              <ref id="bib20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hillery</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Lavelle</surname> <given-names>D</given-names></string-name>, <string-name><surname>Molokie</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dorn</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bressler</surname> <given-names>L</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease</article-title>. <source>Blood</source> <year>2003</year>;<volume>102</volume>:<fpage>3865</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">12907443</pub-id></mixed-citation>
              </ref>
              <ref id="bib21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olivieri</surname> <given-names>NF</given-names></string-name>, <string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Thayalasuthan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Kwiatkowski</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ware</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Kuypers</surname> <given-names>FA</given-names></string-name>, <etal>et al</etal></person-group> <article-title>A pilot study of subcutaneous decitabine in beta-thalassemia intermedia</article-title>. <source>Blood</source> <year>2011</year>;<volume>118</volume>:<fpage>2708</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">21700776</pub-id></mixed-citation>
              </ref>
              <ref id="bib22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saleh</surname> <given-names>MFM</given-names></string-name>, <string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen</article-title>. <source>Clin Case Rep</source> <year>2017</year>;<volume>5</volume>:<fpage>2025</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">29225849</pub-id></mixed-citation>
              </ref>
              <ref id="bib23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Tohme</surname> <given-names>R</given-names></string-name>, <string-name><surname>Tomlinson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sakre</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hasipek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Durkin</surname> <given-names>L</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network</article-title>. <source>Leukemia</source> <year>2021</year>;<volume>35</volume>:<fpage>1023</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">32770088</pub-id></mixed-citation>
              </ref>
              <ref id="bib24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Ebrahem</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>RZ</given-names></string-name>, <string-name><surname>Hasipek</surname> <given-names>M</given-names></string-name>, <string-name><surname>Enane</surname> <given-names>F</given-names></string-name>, <string-name><surname>Radivoyevitch</surname> <given-names>T</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates</article-title>. <source>J Clin Invest</source> <year>2018</year>;<volume>128</volume>:<fpage>4260</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">30015632</pub-id></mixed-citation>
              </ref>
              <ref id="bib25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jones</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Pollyea</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Culp-Hill</surname> <given-names>R</given-names></string-name>, <string-name><surname>Reisz</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Nemkov</surname> <given-names>T</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells</article-title>. <source>Cell Stem Cell</source> <year>2020</year>;<volume>27</volume>:<fpage>748</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">32822582</pub-id></mixed-citation>
              </ref>
              <ref id="bib26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <string-name><surname>Glytsou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>H</given-names></string-name>, <string-name><surname>Narang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Reyna</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Lopez</surname> <given-names>A</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment</article-title>. <source>Cancer Discov</source> <year>2019</year>;<volume>9</volume>:<fpage>890</fpage>–<lpage>909</lpage>.<pub-id pub-id-type="pmid">31048321</pub-id></mixed-citation>
              </ref>
              <ref id="bib27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bogenberger</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Kornblau</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Pierceall</surname> <given-names>WE</given-names></string-name>, <string-name><surname>Lena</surname> <given-names>R</given-names></string-name>, <string-name><surname>Chow</surname> <given-names>D</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>CX</given-names></string-name>, <etal>et al</etal></person-group> <article-title>BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies</article-title>. <source>Leukemia</source> <year>2014</year>;<volume>28</volume>:<fpage>1657</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">24451410</pub-id></mixed-citation>
              </ref>
              <ref id="bib28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lavelle</surname> <given-names>D</given-names></string-name>, <string-name><surname>Vaitkus</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ling</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ruiz</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>KP</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine</article-title>. <source>Blood</source> <year>2012</year>;<volume>119</volume>:<fpage>1240</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22160381</pub-id></mixed-citation>
              </ref>
              <ref id="bib29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ebrahem</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ng</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Saunthararajah</surname> <given-names>Y</given-names></string-name></person-group>. <article-title>High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects</article-title>. <source>Oncotarget</source> <year>2012</year>;<volume>3</volume>:<fpage>1137</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">23087155</pub-id></mixed-citation>
              </ref>
              <ref id="bib30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Griffiths</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Steensma</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Roboz</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Wells</surname> <given-names>R</given-names></string-name>, <string-name><surname>McCloskey</surname> <given-names>J</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study</article-title>. <source>Blood</source> <year>2020</year>;<volume>136</volume>:<fpage>674</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">32285126</pub-id></mixed-citation>
              </ref>
              <ref id="bib31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Molokie</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lavelle</surname> <given-names>D</given-names></string-name>, <string-name><surname>Gowhari</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pacini</surname> <given-names>M</given-names></string-name>, <string-name><surname>Krauz</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hassan</surname> <given-names>J</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study</article-title>. <source>PLoS Med</source> <year>2017</year>;<volume>14</volume>:<fpage>e1002382</fpage>.<pub-id pub-id-type="pmid">28880867</pub-id></mixed-citation>
              </ref>
              <ref id="bib32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hill</surname> <given-names>B</given-names></string-name>, <string-name><surname>Jagadeesh</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pohlman</surname> <given-names>B</given-names></string-name>, <string-name><surname>Dean</surname> <given-names>R</given-names></string-name>, <string-name><surname>Parameswaran</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <etal>et al</etal></person-group> <article-title>A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies</article-title>. <source>Semin Hematol</source> <year>2021</year>;<volume>58</volume>:<fpage>35</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">33509441</pub-id></mixed-citation>
              </ref>
              <ref id="bib33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quintas-Cardama</surname> <given-names>A</given-names></string-name>, <string-name><surname>Santos</surname> <given-names>FP</given-names></string-name>, <string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name></person-group>. <article-title>Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia</article-title>. <source>Leukemia</source> <year>2011</year>;<volume>25</volume>:<fpage>226</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">21116282</pub-id></mixed-citation>
              </ref>
              <ref id="bib34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prebet</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Figueroa</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Ketterling</surname> <given-names>R</given-names></string-name>, <string-name><surname>Melnick</surname> <given-names>A</given-names></string-name>, <string-name><surname>Greenberg</surname> <given-names>PL</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905</article-title>. <source>J Clin Oncol</source> <year>2014</year>;<volume>32</volume>:<fpage>1242</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">24663049</pub-id></mixed-citation>
              </ref>
              <ref id="bib35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Montalban-Bravo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Berdeja</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Abaza</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jabbour</surname> <given-names>E</given-names></string-name>, <string-name><surname>Essell</surname> <given-names>J</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes</article-title>. <source>Cancer</source> <year>2017</year>;<volume>123</volume>:<fpage>994</fpage>–<lpage>1002</lpage>.<pub-id pub-id-type="pmid">28094841</pub-id></mixed-citation>
              </ref>
              <ref id="bib36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Abaza</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Takahashi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Medeiros</surname> <given-names>BC</given-names></string-name>, <string-name><surname>Arellano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Khaled</surname> <given-names>SK</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study</article-title>. <source>Blood Adv</source> <year>2019</year>;<volume>3</volume>:<fpage>508</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">30760466</pub-id></mixed-citation>
              </ref>
              <ref id="bib37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Craddock</surname> <given-names>CF</given-names></string-name>, <string-name><surname>Houlton</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Quek</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Ferguson</surname> <given-names>P</given-names></string-name>, <string-name><surname>Gbandi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Roberts</surname> <given-names>C</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature</article-title>. <source>Clin Cancer Res</source> <year>2017</year>;<volume>23</volume>:<fpage>6430</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">28765326</pub-id></mixed-citation>
              </ref>
              <ref id="bib38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blum</surname> <given-names>W</given-names></string-name>, <string-name><surname>Klisovic</surname> <given-names>RB</given-names></string-name>, <string-name><surname>Hackanson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Devine</surname> <given-names>H</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia</article-title>. <source>J Clin Oncol</source> <year>2007</year>;<volume>25</volume>:<fpage>3884</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">17679729</pub-id></mixed-citation>
              </ref>
              <ref id="bib39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Issa</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Cortes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ravandi</surname> <given-names>F</given-names></string-name>, <string-name><surname>Jabbour</surname> <given-names>E</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia</article-title>. <source>Cancer</source> <year>2015</year>;<volume>121</volume>:<fpage>556</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">25336333</pub-id></mixed-citation>
              </ref>
              <ref id="bib40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sekeres</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Othus</surname> <given-names>M</given-names></string-name>, <string-name><surname>List</surname> <given-names>AF</given-names></string-name>, <string-name><surname>Odenike</surname> <given-names>O</given-names></string-name>, <string-name><surname>Stone</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Gore</surname> <given-names>SD</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117</article-title>. <source>J Clin Oncol</source> <year>2017</year>;<volume>35</volume>:<fpage>2745</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">28486043</pub-id></mixed-citation>
              </ref>
              <ref id="bib41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Esteve</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schots</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bernal Del Castillo</surname> <given-names>T</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J-H</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Dinner</surname> <given-names>S</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy: findings from the safety cohort</article-title>. <source>Blood</source> <year>2018</year>;<volume>132</volume>:<fpage>2736</fpage>.</mixed-citation>
              </ref>
              <ref id="bib42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sallman</surname> <given-names>DA</given-names></string-name>, <string-name><surname>DeZern</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Garcia-Manero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Steensma</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Roboz</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Sekeres</surname> <given-names>MA</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes</article-title>. <source>J Clin Oncol</source> <year>2021</year>;<volume>39</volume>:<fpage>1584</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">33449813</pub-id></mixed-citation>
              </ref>
              <ref id="bib43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dickinson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cherif</surname> <given-names>H</given-names></string-name>, <string-name><surname>Fenaux</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mittelman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>A</given-names></string-name>, <string-name><surname>Portella</surname> <given-names>MSO</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia</article-title>. <source>Blood</source> <year>2018</year>;<volume>132</volume>:<fpage>2629</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">30305280</pub-id></mixed-citation>
              </ref>
              <ref id="bib44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Niu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Drokow</surname> <given-names>EK</given-names></string-name>, <etal>et al</etal></person-group> <article-title>The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells</article-title>. <source>Cancer Manag Res</source> <year>2019</year>;<volume>11</volume>:<fpage>8229</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">31564981</pub-id></mixed-citation>
              </ref>
              <ref id="bib45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roth</surname> <given-names>M</given-names></string-name>, <string-name><surname>Will</surname> <given-names>B</given-names></string-name>, <string-name><surname>Simkin</surname> <given-names>G</given-names></string-name>, <string-name><surname>Narayanagari</surname> <given-names>S</given-names></string-name>, <string-name><surname>Barreyro</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bartholdy</surname> <given-names>B</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation</article-title>. <source>Blood</source> <year>2012</year>;<volume>120</volume>:<fpage>386</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">22627766</pub-id></mixed-citation>
              </ref>
              <ref id="bib46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiNardo</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Jonas</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Pullarkat</surname> <given-names>V</given-names></string-name>, <string-name><surname>Thirman</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Garcia</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>AH</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Azacitidine and venetoclax in previously untreated acute myeloid leukemia</article-title>. <source>N Engl J Med</source> <year>2020</year>;<volume>383</volume>:<fpage>617</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">32786187</pub-id></mixed-citation>
              </ref>
              <ref id="bib47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scuto</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kirschbaum</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kowolik</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kretzner</surname> <given-names>L</given-names></string-name>, <string-name><surname>Juhasz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Atadja</surname> <given-names>P</given-names></string-name>, <etal>et al</etal></person-group> <article-title>The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells</article-title>. <source>Blood</source> <year>2008</year>;<volume>111</volume>:<fpage>5093</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">18349321</pub-id></mixed-citation>
              </ref>
              <ref id="bib48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Choy</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Ngo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Foster</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Marks</surname> <given-names>PA</given-names></string-name></person-group>. <article-title>Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2010</year>;<volume>107</volume>:<fpage>14639</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">20679231</pub-id></mixed-citation>
              </ref>
              <ref id="bib49">
                <label>49.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Conti</surname> <given-names>C</given-names></string-name>, <string-name><surname>Leo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Eichler</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Sordet</surname> <given-names>O</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>A</given-names></string-name>, <etal>et al</etal></person-group> <article-title>Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage</article-title>. <source>Cancer Res</source> <year>2010</year>;<volume>70</volume>:<fpage>4470</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">20460513</pub-id></mixed-citation>
              </ref>
              <ref id="bib50">
                <label>50.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ververis</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hiong</surname> <given-names>A</given-names></string-name>, <string-name><surname>Karagiannis</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Licciardi</surname> <given-names>PV</given-names></string-name></person-group>. <article-title>Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents</article-title>. <source>Biologics</source> <year>2013</year>;<volume>7</volume>:<fpage>47</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">23459471</pub-id></mixed-citation>
              </ref>
              <ref id="bib51">
                <label>51.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asatsuma-Okumura</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>T</given-names></string-name>, <string-name><surname>Handa</surname> <given-names>H</given-names></string-name></person-group>. <article-title>Molecular mechanisms of cereblon-based drugs</article-title>. <source>Pharmacol Ther</source> <year>2019</year>;<volume>202</volume>:<fpage>132</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">31202702</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
